EUVIMEDEUVIMED entdecken
Klinische Studie (Phase II)Klinische Studie (Phase III)Randomisierte kontrollierte StudieOpen Access · CC BY 4.0

Mediators of Filgotinib Treatment Effects in Ulcerative Colitis: Exploring Circulating Biomarkers in the Phase 2b/3 SELECTION Study

Hiroshi Nakase iD, Silvio Danese iD, Walter Reinisch iD, Timothy Ritter, Yan Liang, Emily Wendt, Barrett G Levesque, Oh Kyu Yoon, Yuan Tian, Luting Zhuo, Emmanuel Karouzakis, Yasmina Bauer und 4 weitere

Inflammatory Bowel Diseases · 2025

DOI: 10.1093/ibd/izae278 ↗

Kurz gefasst

Klinische Studie (Phase II) in der Zeitschrift Inflammatory Bowel Diseases, 2025. Verfasst von Hiroshi Nakase und 15 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterology and Hepatology, Sapporo Medical University School of Medicine, Sapporo, Japan. Hauptthemen laut MEDLINE: Colitis, Ulcerative, Biomarkers, Pyridines. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 49 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Gilead Sciences, Inc.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

We utilized patient samples from the large, phase 2b/3 SELECTION trial to identify circulating biomarkers of ulcerative colitis (UC) and potential early mediators of filgotinib treatment effects.

Methods

Samples were collected at baseline and during the induction phase of the SELECTION trial. Evaluated biomarkers comprised serum and stool proteins (measured by enzyme-linked immunosorbent assay), whole-blood cell counts, and whole-blood RNA-seq-derived gene-expression factors identified via exploratory factor analysis. Biomarker levels were assessed by baseline disease severity (endoscopy/bleeding/stool and Mayo Clinic Score) and biologic status (naive vs experienced). Effects of filgotinib on biomarker levels, including week 4 biomarker changes that may mediate week 10 clinical improvements, were assessed.

Results

The biomarker analysis set included 598 biologic-naive patients and 592 biologic-experienced patients. Systemic inflammatory biomarkers (C-reactive protein [CRP], interleukin-6 [IL-6], serum amyloid A [SAA], and platelet cell counts) had the strongest positive correlations with baseline UC disease severity. CRP, IL-6, SAA, and neutrophil activation biomarkers (including neutrophil gelatinase-associated lipocalin [NGAL], tumor necrosis factor ɑ, and oncostatin M [OSM]), as well as platelet, neutrophil, and monocyte cell counts were increased in biologic-experienced versus biologic-naive patients. Gene-expression-derived plasmablast and cell proliferation factors were positively correlated with disease severity; B cell, T-cell activation, and plasmacytoid dendritic cell factors were negatively correlated. Filgotinib reduced nearly all proinflammatory biomarkers correlated with baseline UC disease activity; reduced SAA, CRP, IL-6, NGAL, and OSM at week 4 were identified as mediators of improved week 10 clinical scores.

Conclusions

Filgotinib significantly impacted circulating biomarkers related to UC pathology. Several proinflammatory and neutrophil activation biomarkers may be early mediators of filgotinib treatment effects. ClinicalTrials.gov identifier NCT02914522

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Colitis, UlcerativeBiomarkersPyridinesHumansMaleFemaleAdultMiddle AgedSeverity of Illness IndexC-Reactive ProteinInterleukin-6Serum Amyloid A ProteinFecesTriazoles

Stichwörter der Autor:innen

biomarkersfilgotinibulcerative colitis

Substanzen

BiomarkersGLPG0634PyridinesC-Reactive ProteinInterleukin-6Serum Amyloid A ProteinTriazoles

Autor:innen und Institutionen

  • Department of Gastroenterology and Hepatology, Sapporo Medical University School of Medicine, Sapporo, Japan.
  • Inflammatory Bowel Diseases Center, Humanitas Research Hospital, Milan, Italy.
  • Department of Internal Medicine and Gastroenterology, Medical University of Vienna, Vienna, Austria.
  • GI Alliance Research, Southlake, TX, USA.
  • Gilead Sciences, Inc., Foster City, CA, USA.
  • Galapagos GmbH, Basel, Switzerland.

ORCID-Profile: Hiroshi Nakase, Silvio Danese, Walter Reinisch

Förderung

  • Gilead Sciences, Inc

Zitieren

APA

Nakase, H., Danese, S., Reinisch, W., Ritter, T., Liang, Y., Wendt, E., Levesque, B. G., Yoon, O. K., Tian, Y., Zhuo, L., Karouzakis, E., Bauer, Y., Oortwijn, A., Kaise, T., Malkov, V. A., & Hibi, T. (2025). Mediators of Filgotinib Treatment Effects in Ulcerative Colitis: Exploring Circulating Biomarkers in the Phase 2b/3 SELECTION Study. Inflammatory Bowel Diseases. https://doi.org/10.1093/ibd/izae278

Vancouver

Nakase H, Danese S, Reinisch W, Ritter T, Liang Y, Wendt E, et al. Mediators of Filgotinib Treatment Effects in Ulcerative Colitis: Exploring Circulating Biomarkers in the Phase 2b/3 SELECTION Study. Inflammatory Bowel Diseases. 2025. doi:10.1093/ibd/izae278

BibTeX
@article{Nakase2025,
  author = {Nakase, Hiroshi and Danese, Silvio and Reinisch, Walter and Ritter, Timothy and Liang, Yan and Wendt, Emily and Levesque, Barrett G and Yoon, Oh Kyu and Tian, Yuan and Zhuo, Luting and Karouzakis, Emmanuel and Bauer, Yasmina and Oortwijn, Alessandra and Kaise, Toshihiko and Malkov, Vladislav A and Hibi, Toshifumi},
  title = {Mediators of Filgotinib Treatment Effects in Ulcerative Colitis: Exploring Circulating Biomarkers in the Phase 2b/3 SELECTION Study},
  journal = {Inflammatory Bowel Diseases},
  year = {2025},
  doi = {10.1093/ibd/izae278}
}
Kostenlos starten →